Thomas Otto believes a specialized CDMO can provide efficient solutions to the many challenges surrounding lyophilized substances. But it should be ascertained they have packaging, manufacturing, and lyophilization expertise.
Contributor Cindy H. Dubin talks with some leading Specialty Pharma companies to find out how they are formulating technologies to deter the growing problem of opioid abuse.
EXECUTIVE INTERVIEW – EMD Millipore: Enhancing the Bioavailability of Active Pharmaceutical Ingredients
Drug Development Executive: Steffen Denzinger, Head of Portfolio Development at EMD Millipore, talks about bioavailability challenges and how EMD Millipore’s formulation portfolio and expertise are helping the pharmaceutical industry achieve maximum efficacy with APIs.
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
EXECUTIVE INTERVIEW – Battelle: Innovation in Drug Delivery Through Integrated Science & Engineering
Drug Development Executive: Amy Heintz, PhD, Senior Research Scientist at Battelle, speaks about the company’s relationship with customers and the importance of integrating device design, formulation, and human factors in the development of safe and efficient drug delivery solutions.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part III of III
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., concludes his multiple-part series discussing today’s most challenging issues in solubility.
Brian Reilly and Nathan Wolfe say integrating APIs into a silicone system requires consideration of multiple factors, such as compatibility of the silicone with the API and, more generally, achievement of the prescribed dose delivery rate over the prescribed amount of time. And because different APIs can potentially alter the properties of silicone and vice versa, modification of silicone chemistry may be necessary.
MARKET BRIEF – The Market for Type 2 Diabetes Therapeutics – Key Findings From a Recent Analysis of Global Drug Development Efforts
Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, summarizes key findings of Frost & Sullivan’s recent analysis of the type 2 diabetes therapeutics market, which examines in detail the insulin and non-insulin segments of this market on a global level.
EXECUTIVE INTERVIEW – Catalent Applied Drug Delivery Institute: Helping to Get Better Drugs to Waiting Patients, Encouraging the Adoption of Advanced Delivery Technologies
Drug Development Executive: Kurt Nielsen, PhD, CTO & SVP, Innovation & Growth, and Founding Institute Board Member, discusses the Institute, its goals, structure, and activities.
ABUSE DETERRENT TECHNOLOGY – New Abuse Deterrent Formulation Technology for Immediate-Release Opioids
Johannes Bartholomäus͛, PhD; Sebastian Schwier, PhD; Martin Brett, et al, review how the INTAC technology platform has been extended to IR formulations with the intention to deter non-oral routes of abuse.
EXCLUSIVE ONLINE CONTENT
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
Accenture recently announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its……
Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes……
AC Immune SA recently announced it has received a milestone payment from its partner Life Molecular Imaging in connection with the initiation of….
DURECT Corporation recently announced that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER technology has triggered a $10-million milestone payment from Gilead Sciences, Inc. to…….